Brady Corporation Provides Recast Historical Data for new 24-02-2023, 19:10

Vistra appoints Chief AI & Digital Officer to strengthen client experience and global connectivity   8-04-2026, 15:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00